Vantage Galan 3T, MRT-3020, V8.0 with AiCE Reconstruction Processing Unit for MR

The Vantage Galan 3T, MRT-3020, V8.0, is a 3 Tesla Magnetic Resonance Imaging system designed to acquire high-resolution diagnostic images of the head and body by utilizing nuclear magnetic resonance principles and advanced image processing via its AiCE Reconstruction Processing Unit. This updated system introduces a suite of software innovations including novel artifact suppression techniques (mART EXP, RDC DWI), non-contrast arterial spin labeling (pCASL) for perfusion imaging, iterative motion correction (IMC), and machine learning-driven automated scan planning tools to enhance image quality, streamline workflows, and expand clinical applications.

The Canon Vantage Galan 3T, MRT-3020, V8.0, is a 3 Tesla Magnetic Resonance Imaging (MRI) system designed for diagnostic imaging. It produces cross-sectional, transaxial, coronal, sagittal, and oblique images of anatomical structures throughout the head and body by leveraging nuclear magnetic resonance (NMR) principles, specifically detecting signals from proton density, T1 and T2 relaxation times, flow dynamics, and chemical shifts. The system is capable of both non-contrast enhanced imaging, such as Magnetic Resonance Angiography (MRA), and imaging with contrast agents, providing physicians with critical information for diagnosis. This V8.0 iteration builds upon previous versions, incorporating the AiCE Reconstruction Processing Unit for enhanced image processing. The V8.0 software introduces significant advancements aimed at improving image quality and workflow efficiency. These include new artifact suppression techniques such as mART EXP, a 3D method to reduce susceptibility-induced distortion, and RDC DWI, which minimizes distortion in diffusion-weighted imaging. For non-contrast perfusion imaging, pseudo-continuous Arterial Spin Labeling (pCASL) is implemented. Iterative Motion Correction (IMC) reduces motion artifacts in brain and C-spine imaging. Furthermore, a suite of machine learning-based automated scan planning tools (SureVOI Liver, LiverLine+, ProstateLine+, W-SpineLine+) streamlines exam setup for liver, prostate, and whole spine imaging. Testing confirmed these features perform as intended, with mART EXP showing improved distortion reduction, IMC effectively reducing motion artifacts, RDC DWI reducing DWI distortion, pCASL yielding acceptable CBF values, and automated planning tools providing diagnostic quality images and meeting acceptance criteria. Accessory enhancements include a ceiling camera for patient positioning and tablet applications for remote exam management.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AiCE Reconstruction Processing Unit in V8.0 specifically enhance image quality (e.g., SNR, spatial resolution, contrast-to-noise ratio) for the newly introduced sequences like pCASL and those utilizing mART EXP, compared to reconstructions without AiCE?; What are the quantitative improvements in scan time reduction when mART EXP is combined with Compressed SPEEDER, and how does this combination impact image quality and diagnostic confidence across various anatomies?; For the machine learning-based automated scan planning tools (SureVOI Liver, LiverLine+, ProstateLine+, W-SpineLine+), what is their performance robustness across diverse patient demographics, body habitus, and in the presence of significant anatomical pathologies or prior surgical alterations?; What is the comparative efficacy of Iterative Motion Correction (IMC) for rigid versus non-rigid motion, particularly its limits in correcting complex non-rigid motion in anatomical regions beyond the C-spine where it's explicitly validated for such?; How do the cerebral blood flow (CBF) values obtained using pCASL on this system correlate with established quantitative perfusion techniques (e.g., DSC-MRI or Xenon CT) in healthy volunteers and patient populations with cerebrovascular disease?